(Q37816391)

23 August 2017

1 reference

title

Optimizing antiretroviral therapy in adolescents with perinatally acquired HIV-1 infection (English)

1 reference

23 August 2017

0 references

anti-retroviral agent

0 references

1 reference

Caroline Foster

1

1 reference

23 August 2017

Sarah Fidler

series ordinal

2

1 reference

23 August 2017

publication date

1 December 2010

1 reference

Expert Review of Anti-infective Therapy

23 August 2017

published in

1 reference

23 August 2017

volume

8

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

1403-1416

1 reference

Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Estimating the net effect of HIV on child mortality in African populations affected by generalized HIV epidemics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Adolescent HIV--cause for concern in Southern Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Causes of acute hospitalization in adolescence: burden and spectrum of HIV-related morbidity in a country with an early-onset and severe HIV epidemic: a prospective survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Response to combination antiretroviral therapy: variation by age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Tolerabilities of antiretrovirals in paediatric HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Darunavir: in treatment-experienced pediatric patients with HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

HIV-1 tropism and survival in vertically infected Ugandan infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Changes in the HIV type 1 envelope gene from non-subtype B HIV type 1-infected children in Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

The role of psychosocial and family factors in adherence to antiretroviral treatment in human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Adolescents with a chronic condition: challenges living, challenges treating

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Transition to adult care for youths with diabetes mellitus: findings from a Universal Health Care System.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Improving health outcomes for youth living with the human immunodeficiency virus: a multisite randomized trial of a motivational intervention targeting multiple risk behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Virologic response using directly observed therapy in adolescents with HIV: an adherence tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Disclosure of an HIV diagnosis to children: history, current research, and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Impact of disclosure of HIV infection on health-related quality of life among children and adolescents with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Reproductive health of adolescent girls perinatally infected with HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Neurodevelopmental outcomes in children with HIV infection under 3 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Early language development in children exposed to or infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Effects of perinatal HIV infection and associated risk factors on cognitive development among young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

The impact of AIDS diagnoses on long-term neurocognitive and psychiatric outcomes of surviving adolescents with perinatally acquired HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Neurocognitive function profile in HIV-infected school-age children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Co-occuring psychiatric symptoms in children perinatally infected with HIV and peer comparison sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Rates and types of psychiatric disorders in perinatally human immunodeficiency virus-infected youth and seroreverters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Youth living with HIV and problem substance use: elevated distress is associated with nonadherence and sexual risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Adverse effects of antiretroviral therapy: focus on bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Perinatal outcomes, including mother-to-child transmission of HIV, and child mortality and their association with maternal vitamin D status in Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Effect of human immunodeficiency virus infection on the growth of young children. Duke Pediatric AIDS Clinical Trials Unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Patterns of postnatal growth in HIV-infected and HIV-exposed children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

British HIV Association, BASHH and FSRH guidelines for the management of the sexual and reproductive health of people living with HIV infection 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Cardiovascular disease and HIV infection: host, virus, or drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Cardiovascular complications of AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Increased arterial stiffness in HIV-infected children: risk factors and antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Arterial stiffness and endothelial dysfunction in HIV-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

HIV is associated with thrombophilia and high D-dimer in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Subclinic atherosclerosis and cardiovascular risk factors in HIV-infected children: PERI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Proteinuria in children infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Taking a hard look at the pathogenesis of childhood HIV-associated nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Kidney disease in HIV-positive children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Pregnancies in young women with vertically acquired HIV infection in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

HIV infection and subfertility

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

What happens to children growing up with HIV infection? It’s time for a HAART to heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

O222 Treatment interruption in children with chronic HIV-infection: the results of the paediatric European network for treatment of AIDS (PENTA) 11 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.129

21 January 2018

Identifiers

DOI

10.1586/ERI.10.129

1 reference

release_42vdxzed2jbz7i2oq4qhozlxgi

23 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/42vdxzed2jbz7i2oq4qhozlxgi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference